Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
Cosentyx® - life cycle management to drive growth from 2024
Peak sales potential including all existing and new indications > USD 7bn
GROWTH
*CosentyxⓇ
Indication
Potential
Life cycle development milestones
Hidradenitis Suppurativa (HS)
2022
2023
2024 2025 2026
2027
Giant Cell Arteritis (GCA)
Lupus Nephritis (LN)
2mL AI/PFS & IV expansion
Additional Ph3 indication programs under assessment
<USD 1bn
USD 1-2bn
>USD 2bn
Diagnosed population¹
HS
IV
2mL AI / PFS
GCA
Indication
Patients Unmet need
LN
HS
>400K
GCA
>480K
Debilitating skin disease with significant QoL impact
Eye-sight threatening vasculitis in elderly
LN
>130K
Major cause of morbidity and mortality in SLE patients
Primary readout
Regulatory decisions expected
Ph3
Ph3
EU US
US
US
HS hidradenitis suppurativa.
GCA giant cell arthritis. LN- lupus nephritis. Al auto injector.
PFS prefilled syringe. IV-intravenous formulation (rheumatology indications).
25 Investor Relations | Q4 2022 Results
1. Total diagnosed population G6 countries.
✓ NOVARTIS | Reimagining MedicineView entire presentation